Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices

The programmed death-1 inhibitor pembrolizumab has demonstrated efficacy and safety in clinical trials for treating advanced (unresectable/metastatic) melanoma. We investigated the real-world utilization of pembrolizumab and associated patient outcomes for advanced melanoma in US community oncology...

Descripción completa

Detalles Bibliográficos
Autores principales: Cowey, C. Lance, Liu, Frank Xiaoqing, Black-Shinn, Jenny, Stevinson, Kendall, Boyd, Marley, Frytak, Jennifer R., Ebbinghaus, Scot W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811239/
https://www.ncbi.nlm.nih.gov/pubmed/29252916
http://dx.doi.org/10.1097/CJI.0000000000000204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811239/
https://www.ncbi.nlm.nih.gov/pubmed/29252916
http://dx.doi.org/10.1097/CJI.0000000000000204

Ejemplares similares